Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 655.00
Bid: 658.00
Ask: 659.00
Change: -0.50 (-0.08%)
Spread: 1.00 (0.152%)
Open: 643.00
High: 664.00
Low: 643.00
Prev. Close: 655.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of Debt

5 Aug 2019 15:00

RNS Number : 9418H
Tate & Lyle PLC
05 August 2019
 

5 August 2019

 

TATE & LYLE PLC - ISSUE OF DEBT

 

ISSUE OF DEBT - NOT FOR DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES OF AMERICA (OR TO U.S. PERSONS), AUSTRALIA, CANADA OR JAPAN, OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES OF SECURITIES WOULD BE PROHIBITED BY APPLICABLE LAW.

Tate & Lyle PLC announces that on 1 August 2019 it priced a US$200 million debt private placement. The proceeds will be used to refinance existing indebtedness, thereby extending the Group's debt maturity profile, and for general corporate purposes.

The transaction is expected to complete on 19 November 2019, when the following notes will be issued:

$100 million 3.31% notes due 2029

$100 million 3.41% notes due 2031

Commenting on the issue, Imran Nawaz, Chief Financial Officer, said: "We are delighted by the strong support shown again by private placement investors in Tate & Lyle. The notes will enable us to refinance the £200 million 6.75% bond that matures in November 2019, while maintaining strong levels of liquidity and extending the average maturity of our debt. Issuing fixed-rate notes has allowed us to lock into attractive long-term interest rates, and achieve a cost reduction compared to the maturing debt".

Disclaimer

The notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Act") and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Act. This notice is for information only, does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

END

 

For more information contact Tate & Lyle PLC:

Investor Relations

Tel: +44 (0) 20 7257 2111

 

About Tate & Lyle: 

Tate & Lyle is a global provider of solutions and ingredients for food, beverage and industrial markets.

Tate & Lyle operates through two global divisions, Food & Beverage Solutions and Primary Products, supported by the Innovation and Commercial Development and Global Operations teams. Food & Beverage Solutions is focused on growth by building leading positions globally in the categories of beverages, dairy, and soups, sauces and dressings. Primary Products is focused on delivering steady earnings and generating cash.

Food & Beverage Solutions consists of: Texturants, including speciality starches; Sweeteners, including low- and no-calorie sweeteners; and a Health and Wellness portfolio comprising mainly speciality fibres; and Stabilisers and Functional Systems, which are bespoke ingredient blends that ensure foods retain their structure.

Primary Products consists of high-volume sweeteners, industrial starches and fermentation products (primarily acidulants). It also sells co-products from the corn milling process as animal nutrition.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2019, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IODUGUQWRUPBGWA
Date   Source Headline
3rd Nov 20216:01 pmRNSDirectorate Change
29th Oct 202111:15 amRNSHolding(s) in Company
21st Oct 20214:45 pmRNSRestatement re Primary Products Disposal
18th Oct 20212:30 pmRNSHolding(s) in Company
13th Oct 202112:30 pmRNSHolding(s) in Company
6th Oct 20213:30 pmRNSHolding(s) in Company
6th Oct 202111:15 amRNSDirector/PDMR Shareholding
4th Oct 20212:30 pmRNSDirector/PDMR Shareholding
4th Oct 20217:00 amRNSTotal Voting Rights
30th Sep 202112:00 pmRNSResult of General Meeting
13th Sep 20214:30 pmRNSCircular re. KPS Partnership
1st Sep 20219:58 amRNSTotal Voting Rights
18th Aug 202110:10 amRNSDirector/PDMR Shareholding
11th Aug 20214:00 pmRNSDirector/PDMR Shareholding
2nd Aug 20213:15 pmRNSTotal Voting Rights
29th Jul 202112:45 pmRNSResult of AGM
23rd Jul 20215:00 pmRNSHolding(s) in Company
22nd Jul 20213:15 pmRNSDirector/PDMR Shareholding
16th Jul 20213:30 pmRNSHolding(s) in Company
12th Jul 20214:00 pmRNSHolding(s) in Company
12th Jul 20213:50 pmRNSHolding(s) in Company
12th Jul 20217:00 amRNSTate & Lyle to be re-positioned as growth business
8th Jul 20213:30 pmRNSHolding(s) in Company
8th Jul 20213:14 pmRNSHolding(s) in Company
1st Jul 20214:40 pmRNSBlock listing Interim Review
1st Jul 20214:38 pmRNSTotal Voting Rights
15th Jun 20212:15 pmRNSAnnual Financial Report
14th Jun 20212:05 pmRNSHolding(s) in Company
14th Jun 20212:00 pmRNSHolding(s) in Company
9th Jun 20213:49 pmRNSDirector/PDMR Shareholding
1st Jun 20212:34 pmRNSTotal Voting Rights
27th May 20217:00 amRNSFinal Results
4th May 202111:30 amRNSTotal Voting Rights
28th Apr 202110:00 amRNSDirectorate Change
26th Apr 20217:00 amRNSResponse to media speculation
13th Apr 20213:45 pmRNSHolding(s) in Company
1st Apr 202112:00 pmRNSTotal Voting Rights
25th Mar 202110:00 amRNSDirectorate Changes
23rd Mar 20213:00 pmRNSHolding(s) in Company
12th Mar 202111:00 amRNSDirector Declaration
1st Mar 202111:00 amRNSTotal Voting Rights
26th Feb 202111:00 amRNSDirector Declaration
15th Feb 20214:43 pmRNSHolding(s) in Company
15th Feb 20214:40 pmRNSHolding(s) in Company
15th Feb 20214:37 pmRNSHolding(s) in Company
10th Feb 202111:15 amRNSAcquisition
28th Jan 20217:00 amRNSTrading Statement
21st Jan 20217:00 amRNSVivid Sehgal Appointed Chief Financial Officer
12th Jan 20213:30 pmRNSDirector/PDMR Shareholding
4th Jan 20213:05 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.